REGN7999 が安全で忍容性が高いかどうか、および健康な参加者の体内でどのように機能するかを知るための試験
健康な成人被験者における TMPRSS6 アンタゴニストである REGN7999 の単回漸増用量の安全性、忍容性、薬物動態、および薬力学を評価するための第 1 相、無作為化、二重盲検、プラセボ対照、単一施設試験
The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN7999 in healthy adult participants.
The secondary objectives of the study are:
- To characterize the drug concentration profile of single doses of IV or SC REGN7999
- To assess the immunogenicity of single ascending SC or IV doses of REGN7999
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
-
Ghent、ベルギー、9000
- Drug Research Unit Gent
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Has a body mass index between 18 and 32 kg/m2, inclusive
- Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and electrocardiogram (ECG)s performed at screening and/or prior to administration of initial dose of study drug
- Is in good health based on laboratory safety testing obtained at the screening and baseline visits per the protocol
- Hemoglobin, serum iron, transferrin, serum ferritin, and transferrin saturation, equal to or above the lower limit of the reference range for the participant's age and sex at the local labs, at screening, repeatable once during screening period
- White blood cell (WBC) count, platelet count, red blood cell (RBC) count, hematocrit, and RBC hemoglobin not clinically significantly outside of the reference range in the judgment of the investigator at screening and baseline visits
Key Exclusion Criteria:
-
Pregnant or breastfeeding women
-
Consistent with Clinical Trial Facilitation Group (CTFG) guidance, women of childbearing potential (WOCBP) who are unwilling to practice highly effective contraception, during the study through the end of study (EOS) visit. Highly effective contraceptive measures include:
- stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening;
- intra-uterine device (IUD); intra-uterine hormone-releasing system;
- bilateral tubal ligation or tubal occlusion;
- vasectomized partner (provided that the male vasectomized partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has obtained medical assessment of surgical success for the procedure); and/or
- sexual abstinence as described in the protocol
-
In addition, premenopausal women whose method(s) of birth control is/are associated with ongoing menstruation (eg, combined hormonal contraceptive regimens associated with withdrawal bleeding, non-hormone-releasing IUD, bilateral tubal ligation, bilateral salpingectomy, vasectomized partner, sexual abstinence). Female participants must not be menstruating during the trial, due to being postmenopausal or due to permanent sterilization via hysterectomy, and/or bilateral oophorectomy, or amenorrheic due to use of hormone-releasing IUD, implantable device, or intake of continuous hormonal contraception
-
Sexually active male participants with WOCBP partners who are unwilling to use the following forms of medically acceptable birth control during the study through the EOS visit: vasectomy with medical assessment of surgical success OR consistent use of a condom
-
History of clinically significant cardiovascular (including congestive heart failure and angina), respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, infectious, autoimmune, oncologic, psychiatric or neurological disease, as assessed by the investigator, that may confound the results of the study or poses an additional risk to the participant by study participation.
-
History of chronic anemia, at any time in the past
-
History of RBC transfusion reaction
-
Whole blood donation within the previous 56 days or plasma donation within the previous 7 days prior to screening. Planning on whole blood or plasma donation at any time point during the study.
-
Has a history of significant multiple and/or severe allergies (eg, latex gloves), or has had an anaphylactic reaction to prescription or nonprescription drugs or food
Note: Other protocol-defined Inclusion and Exclusion Criteria apply
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:IV Cohort 1
Single dose REGN7999 or Placebo; randomized 3:1 |
Ascending IV or SC dose administered per protocol Ascending IV or SC dose administered per protocol |
|
実験的:IV Cohort 2
Single dose REGN7999 or Placebo; randomized 3:1 |
Ascending IV or SC dose administered per protocol Ascending IV or SC dose administered per protocol |
|
実験的:IV Cohort 3
Single dose REGN7999 or Placebo; randomized 3:1 |
Ascending IV or SC dose administered per protocol Ascending IV or SC dose administered per protocol |
|
実験的:IV Cohort 4
Single dose REGN7999 or Placebo; randomized 3:1 |
Ascending IV or SC dose administered per protocol Ascending IV or SC dose administered per protocol |
|
実験的:IV Cohort 5
Single dose REGN7999 or Placebo; randomized 3:1 |
Ascending IV or SC dose administered per protocol Ascending IV or SC dose administered per protocol |
|
実験的:SC Cohort 1
Single dose REGN7999 or Placebo; randomized 3:1 |
Ascending IV or SC dose administered per protocol Ascending IV or SC dose administered per protocol |
|
実験的:SC Cohort 2
Single dose REGN7999 or Placebo; randomized 3:1 |
Ascending IV or SC dose administered per protocol Ascending IV or SC dose administered per protocol |
|
実験的:SC Cohort 3
Single dose REGN7999 or Placebo; randomized 3:1 |
Ascending IV or SC dose administered per protocol Ascending IV or SC dose administered per protocol |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with REGN7999 or placebo
時間枠:Through the end of study visit, week 20
|
IV cohorts 1 to 4 SC cohorts 1 and 2 |
Through the end of study visit, week 20
|
|
Incidence and severity of TEAEs in participants treated with REGN7999 or placebo
時間枠:Through the end of study visit, week 26
|
IV cohort 5 and SC cohort 3 |
Through the end of study visit, week 26
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Concentrations of REGN7999 in serum
時間枠:Through the end of study visit, week 20
|
IV cohorts 1 to 4 for SC cohorts 1 and 2 |
Through the end of study visit, week 20
|
|
Concentrations of REGN7999 in serum
時間枠:Through the end of study visit, week 26
|
IV cohort 5 and SC cohort 3 |
Through the end of study visit, week 26
|
|
Incidences of anti-drug antibodies (ADA) to REGN7999 over time
時間枠:Through the end of study visit, week 20
|
IV cohorts 1 to 4 for SC cohorts 1 and 2 |
Through the end of study visit, week 20
|
|
Incidences of anti-drug antibodies (ADA) to REGN7999 over time
時間枠:Through the end of study visit, week 26
|
IV cohort 5 and SC cohort 3 |
Through the end of study visit, week 26
|
協力者と研究者
捜査官
- スタディディレクター:Clinical Trial Management、Regeneron Pharmaceuticals
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- R7999-HV-2154
- 2022-500398-15-00 (その他の識別子:EUCT Number)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD 共有時間枠
When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
IPD 共有アクセス基準
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。